Introduction {#Sec1}
============

On 31 December 2019, the World Health Organization (WHO) China Country Office was informed of cases of pneumonia of unknown etiology (unknown cause) detected in Wuhan City, Hubei Province of China. The causal agent was identified as a novel coronavirus (2019-nCOV) on 7 January 2020 \[[@CR1]\]. 2019-nCOV was renamed as the SARS-Cov-2 virus and disease caused as COVID-19, most likely a zoonotic disease \[[@CR2], [@CR3]\]. On 30 January 2020, following the recommendations of the Emergency Committee, the WHO Director-General declared that the outbreak constitutes a Public Health Emergency of International Concern (PHEIC) or pandemic \[[@CR4]\]. There has been an unexpected and exponential rise in the number of cases all over the globe, with over 1.8 million cases worldwide and more than 0.11 million fatalities \[[@CR5]\]. The impact of COVID-19 is substantial and has already caused significant economic, social, and health-care disruptions worldwide \[[@CR6]--[@CR8]\]. India's first COVID-19 case was found on 30 January 2020. The surge reached 14,352 confirmed COVID cases with 486 deaths at the time of submission of this study, i.e., 17 April 2020, generating a case-fatality rate of 3% \[[@CR9]\].

Methodology {#Sec2}
===========

We conducted a cross-sectional self-administered online survey for this study purpose in the first week of April 2020. The survey was piloted and further refined based on feedback among expert gynecologic oncology colleagues. The self-administered survey posed groups of questions on various challenges about management changes regarding gynecologic cancers, concerns about personal protection measures, and social perspectives. Questions with ambiguous intent or options were refined. The survey was disbursed through [www.surveymonkey.com](http://www.surveymonkey.com) to personal mail addresses of members of The Association of Gynecological Oncologists of India (AGOI) and WhatsApp groups. There was a set of closed and open-ended questions whose answers could be marked on a numerical scale. At the end of the survey period, responses received were downloaded as a form of comma-separated values (CSV) file. Data were analyzed using Microsoft Office Excel 2016. Results were expressed as percentages of total responses excluding blank or unattended response. Overall theme-specific responses were expressed as a spectrum of finding and related inferences were drawn.

Results {#Sec3}
=======

We sent the survey to 567 AGOI members (electronic mail recipients and members of the AGOI WhatsApp group), 520 finally received survey links (47 emails bounced or participants opted out of survey). We received 90 responses, yielding a net response rate of 12%. Among respondents, Gynecological oncologists were 68%, Gynecologists 12%, Surgical Oncologists 11%, and finally Medical Oncologists and Radiation Oncologists 4% each. Half of the respondents were from the academic hospital, followed by the cancer center (31%), private hospitals (15.56%), and 3% from local or regional hospitals. 49% of respondents were consultants with experience of 10 years or more, while 23% were consultants with below ten years of experience, and 19% were residents and 9% fellows.

The majority of respondents (75%) told to have been following institutional or national guidelines; rest (25%) were following some international guidelines. 60% of respondents expressed a lack of scientific evidence among guidelines.

Tele-consultation services were reported to have been started by 58% of respondents, while 16% told to have facility under process. 'New cancer cases' were being seen by 44% of respondents in accordance with institutional guidelines, 35% were deferring to see these patients, and 21% had not got any new case at the time of this survey. Cervical Intraepithelial Neoplasia-3 (CIN-3) was being managed conventionally by 30%, while 65% of respondents were postponing definitive management by three months.

Early-Stage Cervical Cancer {#Sec4}
---------------------------

Standard surgical management was reported by 34% of respondents, 33% were offering chemoradiotherapy for all cases, and the remaining were following neoadjuvant chemotherapy or radical radiotherapy (RT). (Table [1](#Tab1){ref-type="table"}).Table 1Distribution of various treatment modalities for 'Early-stage' disease (percentages of responses received)MalignancyManagement options (% responses)CervixConventional surgery still being done at my center (34)CCRT for all (33)NACT followed by delayed surgery (28)NART followed by delayed surgery (6)EndometriumConventional surgery still being done at my center (48)LNG IUS followed by delayed surgery (15)NACT followed by delayed surgery (16)Neo-adjuvant hormone therapy followed by delayed surgery (22)VulvaConventional surgery still being done at my center (28)Close observation followed by surgery at earliest opportunity (40)NACT followed by delayed surgery (14)NART followed by delayed surgery (18)

Early-Stage Endometrial Cancer {#Sec5}
------------------------------

Almost half of the respondents (48%) were continuing standard surgery, others were offering neoadjuvant hormonal therapy (22%) or neoadjuvant chemotherapy followed by delayed surgery (16%), and Levonorgestrel Intrauterine system (LNG-IUS) followed by surgery (15%) (Table [1](#Tab1){ref-type="table"}).

Early-Stage Vulvar Cancer {#Sec6}
-------------------------

40% were following close observation, 28% were continuing to offer standard surgery, and the rest (32%) were offering neoadjuvant options with chemo or RT. (Table [1](#Tab1){ref-type="table"}).

Most respondents (83--92%) continued to treat advanced-stage gynecological cancers, though most of them have \'modified\' standard management as per institutional protocols. (Fig. [1](#Fig1){ref-type="fig"}). Most respondents (80%) felt strongly about 'cessation of elective benign surgeries' and 70% for \'cessation of cancer surgeries.\' Most respondents (68%) were not in favor of postponing diagnostic services for \'new\' patients. Most (82%) supported the suspension or modification of standard \'follow-up protocols\' of gynecological cancer patients.Fig. 1Management options for 'Advanced' stage disease

71% of respondents felt that elective benign surgeries should be postponed \'as long as necessary,\' to divert resources for COVID care. However, only 37% felt a delay of two weeks is acceptable for cancer surgeries, and another 36% felt these surgeries could be delayed for six weeks. New patients\' diagnostic services could be delayed up to two weeks, was reported by 52% of respondents, and 27% felt a delay of six weeks was acceptable.

Most respondents have modified \'follow-up\' protocols, mostly with a \'less frequent\' follow-up approach. Patients with more than five years of disease-free survival were not being seen presently by 54% of respondents. (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Suggested follow-up protocol, post-treatment completion, weighing positive as well as negative consequences

Personal protection equipment (PPE) usage as a preventive measure against contracting COVID-19 was suggested by 75% of respondents when dealing with suspected/confirmed COVID patients. Another 22% reported that all HCW should use PPE at all times during health care delivery. Most respondents (92%) believed that a combination of social distancing, face mask (any type), and hand hygiene was an effective means to contain the pandemic.

Only 3% of respondents reported having operated on a confirmed COVID case at the time of answering this survey, while another 4% were awaiting COVID test results on their patients. Current Hydoxy-chloroquine (HCQ) prophylaxis use was reported by 22% of respondents, 50% wished to take it but were waiting for more robust evidence to support its use, 12% wanted to take it but were concerned about cardiac toxicity, and 16% did not want to take it at all.

Various alternative learning methods were suggested by respondents as depicted in Fig. [3](#Fig3){ref-type="fig"}. 54% of respondents felt that these alternative learning methods were not good enough, as there would be \'less opportunity for professional interaction,\' 42% were concerned about different geographic time zones during online events, 48% were worried about acquiring new digital/social media skills to be part of e-learning, and lastly, 26% felt that there would be less opportunity for networking in e-learning events.Fig. 3Alterative learning methods if lock-down/travel restrictions extend beyond 6 months

Discussion {#Sec7}
==========

AGOI mostly consists of practicing Gyn-oncologists, gynecologists with a particular interest in Gyn- oncology or preventive oncology, surgical oncologists, medical and radiation oncologists. It was encouraging that two-thirds of the respondents (67%) were practicing Gyn-oncologists. More than 80% of respondents were from academic institutions or cancer centers. One in two respondents had an experience of more than ten years, which gave a realistic view of the impact of the pandemic on clinical practice in gynecological oncology. At the time of the survey, many centers and institutions in India were in the process of formulating their guidelines/webinars or published guidelines that resembled the logistics of their working environment \[[@CR9]\]. Hence two-third of respondents were following some COVID cancer guidelines to manage gynecological cancers \[[@CR10]--[@CR19]\]. Bench to bedside research on COVID-19 was being generated fast track in the world, making clinicians uncomfortable as they were not used to this speed. This might be why 60% of respondents expressed a lack of scientific evidence among existing guidelines.

Cervical cancer was reportedly managed with standard optimal therapy (surgery/chemo-radiation), in two-thirds of the patients \[[@CR20], [@CR21]\]. One third were given neoadjuvant chemotherapy to delay surgery, which is not the standard of care presently, but is a valid alternative if resources are stretched \[[@CR22]\]. With regards to early endometrial cancer, surgery is the mainstay of treatment and preferably Minimally Invasive Surgery (MIS) \[[@CR23]\], but only one in two underwent surgery. Some form of therapy was advocated (hormonal/NACT) so that surgery could be delayed \[[@CR24]\]. There are concerns with the safety of MIS regarding smoke evacuation and intra-abdominal pressure, which might have altered the clinician\'s decision to delay MIS \[[@CR25]\]. Many early vulvar cancers were managed by observation, and only a few received surgery or neoadjuvant therapy. Vulvar cancers constitute less than 10% of the surgical workload, so interpretation is difficult as numbers treated during this time might be few. On speculation, the elderly age group delayed healing of the surgical wound, and prolonged hospitalization might have shifted the balance towards observation with intent to delay surgery compared to the cervix or endometrium \[[@CR26]\].

Amongst all interventions in early-stage gynecological cancers, surgery, when indicated, appears to be the best possible solution where recovery from surgery is good, and the probability of acquiring the virus is less in a screened patient. There is an increased risk of acquiring viral infection as RT requires multiple hospital visits, chemotherapy suppresses immunity, and increases susceptibility to infection \[[@CR13], [@CR14]\]. There might have been obvious logistic reasons for following one treatment over the other such as lack of availability of slots to treat, inability to travel to a center with RT or surgical facility, or reduced number of medical/nursing staff working due to quarantine and lockdown issues. The overall oncological outcomes of early gynecological cancers are excellent; hence they need to be evaluated and compared to pre-COVID literature as there are deviations from standard management now globally. It would remain to be seen how many patients developed COVID-19 due to cancer-related treatment and contributed to overall morbidity and mortality.

There is not much controversy in starting treatment for advanced gynecological cancers in the survey results. Most of these comprise of advanced ovarian cancers, and neoadjuvant treatment is non-inferior to extensive cytoreductive surgery \[[@CR27]\]. There is a clause on performing extensive cytoreductive surgery (CRS) during the pandemic as intensive care beds need to be reserved, preferably for COVID patients. Reduced blood donation camps leading to a shortage of blood products also is a limiting factor for performing CRS with or without HIPEC.\[[@CR13], [@CR14]\]. Increased susceptibility to the virus is the main concern in advanced ovarian cancer patients as they are generally over 60 years, frail, and immune-suppressed during chemotherapy \[[@CR28]--[@CR30]\].

More than 70% of respondents felt that a delay of two to six weeks in the active treatment of gynecological cancers is acceptable. This is in keeping with cancer guidance of referral to treatment of 30-day cutoff in most developed countries for starting active intervention from diagnosis and also the time frame for advocating adjuvant therapy \[[@CR14]--[@CR16]\].

As expected, the response rate to either postponement or modifications in the \'follow-up\' of treated patients was high. Despite many years of discussion, there is always resistance to change traditional physical follow up methods all over the world \[[@CR31]\]. Now, the pandemic has changed the way we work by incorporating telemedicine \[[@CR32]\]. Whether this will permanently change the way we consult patients in the future remains to be seen \[[@CR30]\]. This appears to be a reasonable learning period for tele-follow-ups for cancer survivors for many cancer centers in India \[[@CR9]\].

Most practitioners in the survey felt that general measures effectively contained the pandemic in day to day practice and complete PPEs to be reserved for workers dealing with high-risk patients. A common sense, rationed approach to the availability of resources like PPEs and the magnitude of this pandemic is being followed cautiously not only in India but all over the world \[[@CR33], [@CR34]\]. There was a mixed response to HCQ prophylaxis as the evidence and availability are an issue \[[@CR35], [@CR36]\]. It has been recommended both by CDC and ICMR, after showing promise in several studies in vivo \[[@CR37], [@CR38]\]. But there have been certain concerns raised about potential cardiac side effects, especially in combination with azithromycin or individual with underlying cardiac conditions. Responders have shown similar concerns. Studies on HCQ prophylaxis are still evolving, and there is no consensus worldwide on HCQ prophylaxis for health care workers.

As per GLOBOCAN estimates, India had 96,922 new cervical cancers, 36,170 new ovarian cancers, and 13,328 new endometrial cancers in 2018 \[[@CR39]\]. The ongoing pandemic has forced a delay in cancer management due to several reasons cited above. This is likely to have an adverse effect on overall cancer care. We may soon be facing a bi-modal peak of cancer deaths; the imminent spike of those with decimated immunity falling victim to Covid-19 and the latent toll on those whose treatments were de-intensified, delayed or canceled altogether. To survive SARS-CoV-2 only to then succumb to an undertreated cancer would be a Pyrrhic victory. The acuteness of infection and the chronicity of malignancy are the Scylla and Charybdis between which oncologists and their patients must now chart a very cautious course indeed \[[@CR40]\].

Conclusions {#Sec8}
===========

These are unprecedented times for health-care, even more so for the oncology community. We have to adapt to the requirements of patients, caregivers, and institutions, in consonance with the stage of ongoing pandemic. Multi-disciplinary tumor board discussions, keeping patients involved in decision-making, and adopting a safe approach for both patients and health care workers will be vital in overcoming the crisis.
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